Chas Pulido
General Partner at Alix Ventures
San Francisco, California
Overview
Work Experience
Investor
2024 - Current
“Stealth”
Founder & General Partner
2020
Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology & biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is built of Life Science Founders with experience in raising capital, scaling teams, running labs, partnering with Pharma, & the many fires that consist of operating an early stage company. SAB: Composed of Bioengineering PhDs turned Founders, our Scientific Advisory Board provides deep technical expertise & fluency across a wide variety of Life Science sub-domains from platforms for “Novel Applications” (Therapeutics/Diagnostics) to “Bio-Economy Infrastructure” (Tools/Services/Manufacturing). Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large Payors. Limited Partners: Anchored by leading strategic LPs making up some of the best venture capital firms in the world, veteran founders, & industry experts. Alix is here to fill the void for early stage Life Science capital.
Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Drive Radical Advances in Human Health
Creator
2020
Uniting the Life Science ecosystem in #PatientImpact — Spotlighting leaders in Academia, Startups, Pharma, & VC — By Alix Ventures
Investor
2021
"Enhancing Therapeutic Potency Through Conditional Activation" Co-Investors: Viking Global, Foresite Capital, Perceptive Advisors, Venrock, First Round, OMX, Lifeforce, amongst others
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.
Raised $126,599,251.00 from Venrock Healthcare Capital Partners, Venrock, First Round Capital, Foresite Capital, OMX Ventures, Refactor, Perceptive Advisors, Highside Capital Management, Viking Global Investors and Lifeforce Capital.
Investor
2022
"Enabling Logic Gated Gene Therapy" Co-Investors: FPV, Playground, Redmile, Eli Lilly, amongst others
Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.
Raised $104,200,000.00 from Potentum partners, Playground Global, Eli Lilly & Company Foundation, FPV Ventures, Redmile Group, BeiGene, ANRI and Camford Capital.
Investor
2020
"Enabling Full Stack DNA Writing" Co-Investors: a16z, 8VC, KdT, amongst others
Elegen is a biotechnology company that develops microfluidic technology.
Raised $37,000,000.00 from 8VC, KdT Ventures, Triatomic Capital, ACVC Partners, Andreessen Horowitz, Alix Ventures, Digitalis Ventures, Agilent Technologies, John Ballantyne and AME Cloud Ventures.
Investor
2023
“Enabling Ultra-High Throughput Chemical Synthesis” Co-Investors: Stealth
Investor
2022
"Enabling Genomic Insights for Under Represented Populations" Co-Investors: F-Prime, Digitalis, AME Cloud, amongst others
Galatea Bio’s mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics.
Raised $20,656,000.00 from F-Prime Capital, Digitalis Ventures, Pareto Holdings and Edward Lando.
First Investor
2021
"Enabling Ultra-High Throughput Single Cell Screening & Manipulation" Co-Investors: Stealth
Zafrens offers a throughput platform for cell characterization, correlating molecular profiles to phenotype for accelerated drug discovery.
Raised $29,000,000.00 from Prime Movers Lab, BlueYard Capital, Global Brain Corporation, Iaso Ventures, Alix Ventures, KOFA Healthcare, Possible Ventures, Hawktail Management and FoundersX Ventures.
Investor
2023
"Enhancing Therapeutic Efficacy By Targeting Tumor Acidity" Co-Investors: Stealth
Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics.
Raised $6,835,171.00 from Connecticut Innovations.